Publications by authors named "P Plezia"
Article Synopsis
- Bevacizumab, a drug that inhibits VEGF-A, combined with chemotherapy has shown improved survival rates for patients with metastatic colorectal cancer (mCRC), but researchers are exploring another dual-blocker, vanucizumab, which targets both VEGF-A and angiopoietin-2 (Ang-2).
- In a phase II trial, 189 patients received either vanucizumab plus modified FOLFOX-6 chemotherapy or bevacizumab plus the same chemotherapy, with progression-free survival (PFS) as the main outcome measure.
- Results indicated that both treatments had similar PFS outcomes and safety profiles, with favorable response rates, but vanucizumab did not show significant advantages over bevacizumab
Purpose: To perform a phase I and pharmacokinetics study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) a new ribonucleotide reductase inhibitor using a single intravenous (2-h) schedule every 4 weeks. 3-AP was given at a starting dose of 5 mg/m(2) with escalation based on a modified Fibonacci scheme.
Patients And Methods: A total of 27 patients with advanced cancer were entered into the study.
Dolasetron mesylate (MDL 73,147, Anzemet, Hoechst Marion Roussel, Kansas City, MO) is a 5-HT ( 3 ) receptor antagonist undergoing clinical evaluation as an antiemetic agent. Dolasetron is rapidly metabolized to form hydrodolasetron (MDL 74,156). The pharmacokinetics of hydrodolasetron were studied after administration of a single intravenous infusion of 0.
View Article and Find Full Text PDFThis randomized, double-blind, parallel-group, multicenter study compared the antiemetic effectiveness, safety, and tolerability of two different intravenous (i.v.) doses of dolasetron mesylate (0.
View Article and Find Full Text PDF